This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Sesen Bio Crecimiento futuro
Future controles de criterios 0/6
Información clave
19.3%
Tasa de crecimiento de los beneficios
4.4%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 23.7% |
| Tasa de crecimiento de los ingresos | -85.7% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 28 Feb 2023 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Sesen Bio and Carisma Therapeutics announce merger agreement
Sep 21Sesen Bio GAAP EPS of -$0.16 misses by $0.03
Aug 08Sesen Bio granted additional time period for regaining compliance
Jul 27Sesen Bio slips after decision to pause U.S. studies for lead asset
Jul 18Sesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives
Jun 02We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully
Apr 17
We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate
Dec 05Sesen Bio: Interesting Price Drop After CRL
Nov 24Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022
Nov 17Sesen Bio: The Road Ahead
Aug 23Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00
Aug 12Sesen Bio: Binary Event Approaching
Jun 13Sesen Bio inks global supply partnership with Qilu Pharmaceutical
Jun 02Sesen Bio EPS misses by $0.27
May 10Sesen Bio: Long-Term And Short-Term Potential In Advance Of Its First PDUFA
May 07News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat
Feb 18Sesen announces positive FDA meeting for vicineum's marketing application
Feb 01Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?
Jan 26Sesen Bio/Qilu Pharma's Vicineum IND application accepted for review in China
Jan 13Sesen Bio files US application for its Vicineum in bladder cancer
Dec 21Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook
Dec 21
Sesen Bio: A Look At Vicineum's Potential
Nov 29Sesen Bio, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 09Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2025 | N/A | -9 | -18 | N/A | 1 |
| 12/31/2024 | N/A | -8 | -8 | N/A | 1 |
| 12/31/2023 | N/A | -26 | -20 | N/A | 1 |
| 12/31/2022 | 40 | -20 | 25 | 25 | N/A |
| 9/30/2022 | 60 | -3 | 10 | 10 | N/A |
| 6/30/2022 | 20 | 48 | -29 | -29 | N/A |
| 3/31/2022 | 22 | 54 | -43 | -43 | N/A |
| 12/31/2021 | 27 | 0 | -69 | -69 | N/A |
| 9/30/2021 | 7 | -24 | -65 | -65 | N/A |
| 6/30/2021 | 18 | -118 | -54 | -54 | N/A |
| 3/31/2021 | 16 | -119 | -40 | -40 | N/A |
| 12/31/2020 | 11 | -23 | -31 | -31 | N/A |
| 9/30/2020 | 11 | -41 | -36 | -36 | N/A |
| 6/30/2020 | N/A | -32 | -39 | -39 | N/A |
| 3/31/2020 | N/A | -60 | -39 | -38 | N/A |
| 12/31/2019 | N/A | -107 | -38 | -38 | N/A |
| 9/30/2019 | N/A | -81 | -32 | -31 | N/A |
| 6/30/2019 | N/A | -82 | -30 | -30 | N/A |
| 3/31/2019 | N/A | -36 | -26 | -26 | N/A |
| 12/31/2018 | N/A | -34 | -23 | -23 | N/A |
| 9/30/2018 | N/A | -33 | -19 | -19 | N/A |
| 6/30/2018 | N/A | -29 | -18 | -18 | N/A |
| 3/31/2018 | N/A | -27 | -17 | -17 | N/A |
| 12/31/2017 | 0 | -29 | -18 | -18 | N/A |
| 9/30/2017 | 1 | -26 | -20 | -20 | N/A |
| 6/30/2017 | 30 | 3 | 6 | 6 | N/A |
| 3/31/2017 | 30 | 3 | 6 | 6 | N/A |
| 12/31/2016 | 30 | 2 | 3 | 3 | N/A |
| 9/30/2016 | 30 | -5 | N/A | -1 | N/A |
| 6/30/2016 | 1 | -34 | N/A | -31 | N/A |
| 3/31/2016 | 1 | -35 | N/A | -35 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: SESN is forecast to remain unprofitable over the next 3 years.
Beneficios vs. Mercado: SESN is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: SESN is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: SESN is forecast to have no revenue next year.
Ingresos de alto crecimiento: SESN is forecast to have no revenue next year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if SESN's Return on Equity is forecast to be high in 3 years time